Transfusion Reaction: What You Need to Know

What is Transfusion Reaction?

A transfusion reaction is an adverse response that occurs during or shortly after a blood product transfusion (red blood cells, platelets, plasma, or cryoprecipitate). The reaction can involve the immune system, the circulatory system, or other organ systems and may range from mild (e.g., fever, chills) to life‑threatening (e.g., anaphylaxis, acute hemolytic reaction). Prompt recognition and management are essential because some reactions progress rapidly.

According to the Mayo Clinic, transfusion reactions are the most common complications of blood transfusion, affecting roughly 1–3% of all transfused patients, but the true incidence may be higher because mild reactions are sometimes missed.

Common Causes

Most transfusion reactions are predictable and preventable. Below are the most frequently encountered causes, grouped by mechanism.

• Acute hemolytic reaction – Recipient antibodies destroy donor red cells (usually ABO incompatibility).
• Febrile non‑hemolytic reaction (FNHR) – Cytokines released from donor leukocytes stimulate fever and chills.
• Allergic reaction – IgE‑mediated response to plasma proteins; may be mild (urticaria) or severe (anaphylaxis).
• Transfusion‑related acute lung injury (TRALI) – Antibodies in donor plasma activate recipient neutrophils, causing non‑cardiogenic pulmonary edema.
• Transfusion‑associated circulatory overload (TACO) – Volume overload in patients with limited cardiac reserve.
• Delayed hemolytic reaction – Recipient forms antibodies days to weeks after transfusion, leading to gradual red‑cell destruction.
• Septic reaction – Bacterial contamination of the blood product.
• Transfusion‑related graft‑versus‑host disease (TR‑GVHD) – Donor lymphocytes attack recipient tissues; rare but highly fatal.
• Hypotensive reaction – Usually related to bradykinin accumulation during plasma transfusion, more common in patients receiving ACE inhibitors.
• Hemolysis due to storage lesion – Degraded red‑cell membranes release hemoglobin and potassium, potentially causing renal injury.

Associated Symptoms

The clinical picture varies with the underlying cause. Commonly reported symptoms include:

• Fever, chills, or rigors
• Flushing, itching, or hives (urticaria)
• Dyspnea, cough, or wheezing
• Chest or back pain
• Low blood pressure (hypotension) or rapid heartbeat (tachycardia)
• Dark urine (hemoglobinuria) indicating hemolysis
• Nausea, vomiting, or abdominal pain
• Headache, confusion, or seizures (rare, usually in severe hemolysis or anaphylaxis)

When to See a Doctor

Any new or worsening symptom that starts during a transfusion—or within 24 hours afterward—should be reported immediately to the bedside nurse or physician. Seek urgent medical care if you notice:

• Fever ≥38 °C (100.4 °F) accompanied by chills
• Sudden shortness of breath, wheezing, or chest tightness
• Severe itching, hives, or swelling of the lips/face
• Rapid drop in blood pressure or feeling faint
• Dark, tea‑colored urine
• Severe back or flank pain
• Unexplained mental status changes (confusion, agitation)

These signs can herald a serious reaction that requires immediate intervention.

Diagnosis

Diagnosing a transfusion reaction is a stepwise process that combines clinical assessment with laboratory testing.

1. Immediate Clinical Assessment

• Stop the transfusion at the first sign of a reaction.
• Document vital signs, time of symptom onset, and the specific blood component being infused.
• Obtain a focused physical exam (cardiac, pulmonary, skin, neurological).

2. Laboratory Evaluation

• Direct Antiglobulin Test (DAT) / Coombs test: Detects antibodies or complement bound to patient’s red cells—positive in hemolytic reactions.
• Serum bilirubin, LDH, haptoglobin: Hemolysis markers; elevated bilirubin/LDH and low haptoglobin support red‑cell destruction.
• Blood cultures: Performed when septic reaction is suspected.
• Chest X‑ray: Evaluates for pulmonary infiltrates in TRALI or TACO.
• Urinalysis: Detects hemoglobin or myoglobin in urine.
• Repeat blood typing and antibody screen: Confirms ABO compatibility and identifies new alloantibodies.

3. Transfusion Service Review

The blood bank reviews the product’s identification, storage conditions, and post‑transfusion investigations, such as:

• Sample of the implicated unit for sterility testing.
• Cross‑match re‑evaluation.

Treatment Options

Management depends on the type and severity of the reaction. The primary goals are to stop the offending transfusion, treat symptoms, and prevent complications.

General Measures

• Stop the transfusion immediately. Keep the IV line open with normal saline to maintain access.
• Notify the transfusion service and the treating physician.
• Document the event thoroughly (time, product, signs, interventions).

Specific Treatments

• Acute hemolytic reaction – Aggressive IV hydration, urine alkalinization, and monitoring for renal failure. In severe cases, consider steroids or plasma exchange.
• FNHR – Antipyretics (acetaminophen) and, if needed, antihistamines. Future transfusions may be leukoreduced.
• Allergic reaction – Antihistamines (diphenhydramine) for mild cases; epinephrine 0.3 mg IM for anaphylaxis, followed by airway monitoring.
• TRALI – Supportive care with supplemental oxygen, possible non‑invasive ventilation, and close hemodynamic monitoring. Diuretics are avoided because the problem is not volume overload.
• TACO – Diuretics (e.g., furosemide), oxygen, and, if needed, brief CPAP or mechanical ventilation.
• Septic reaction – Broad‑spectrum antibiotics initiated promptly after cultures are drawn; consider antifungals if fungal contamination is suspected.
• Delayed hemolytic reaction – Usually self‑limited; monitor hemoglobin and supportive care. If severe anemia occurs, a compatible red‑cell unit may be required.
• TR‑GVHD – No effective treatment; prevention (irradiated blood components) is key.
• Hypotensive/bradykinin reaction – Stop ACE inhibitors temporarily; administer antihistamines and, if needed, vasopressors.

Home Care (after discharge)

• Stay hydrated (2–3 L of water daily) unless otherwise instructed.
• Monitor urine color; report dark urine promptly.
• Take prescribed antihistamines or analgesics as directed.
• Schedule follow‑up labs (CBC, renal function, bilirubin) within 48–72 hours.

Prevention Tips

Most transfusion reactions can be reduced with careful planning and adherence to safety protocols.

• Accurate patient identification: Verify name, medical record number, and ABO type at least two times before starting the transfusion.
• Use leukoreduced blood products: Removes most white‑blood‑cell cytokines, decreasing FNHR rates.
• Pre‑medication only when indicated: Routine antihistamines or antipyretics are not recommended for every patient; they mask early signs of serious reactions.
• Limit transfusion volume and rate: Particularly in elderly, pediatric, or cardiac‑ compromised patients to avoid TACO.
• Screen for rare antibodies: Patients with a history of multiple transfusions or pregnancies may need an extended antibody screen.
• Use irradiated products for at‑risk groups: Prevents TR‑GVHD in immunocompromised patients and neonates.
• Maintain proper storage and handling: Blood components must be kept at recommended temperatures; any breach can promote bacterial growth.
• Educate patients: Encourage patients to voice any new sensations during transfusion and to keep a copy of their transfusion reaction history for future encounters.

Emergency Warning Signs

Key Take‑aways

• Transfusion reactions vary from mild fever to fatal anaphylaxis.
• Early recognition, stopping the transfusion, and rapid medical evaluation are critical.
• Laboratory tests (DAT, cultures, imaging) help pinpoint the underlying mechanism.
• Treatment is tailored to the reaction type—hydration for hemolysis, epinephrine for anaphylaxis, antibiotics for sepsis, etc.
• Prevention (accurate identification, leukoreduction, appropriate product selection) reduces risk dramatically.

For more detailed information, visit trusted resources such as the Mayo Clinic, the CDC, the NIH, and the World Health Organization.